NasdaqCM:SLNOBiotechs
Will Vykat XR Approval and Board Shift Reshape Soleno Therapeutics' (SLNO) Investment Narrative?
Earlier this month, Soleno Therapeutics announced the passing of long-serving director and Audit Committee Chair William G. Harris, while indicating that existing Audit Committee member Andrew Sinclair, who qualifies as an “audit committee financial expert,” is expected to assume the chair role.
At the same time, the company has attracted uniformly positive analyst attention following FDA approval of Vykat XR, currently the only approved therapy for hyperphagia in Prader-Willi syndrome,...